Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Cartesian Therapeutics, Inc. Director's Dealing 2023

Nov 15, 2023

33483_dirs_2023-11-15_eab56add-d8d5-4ebe-ac78-f22c08f54429.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cartesian Therapeutics, Inc. (RNAC)
CIK: 0001453687
Period of Report: 2023-11-13

Reporting Person: BARABE TIMOTHY C (Director)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-11-13 Stock Option (Right to Buy) $11 D 10328 Disposed 2026-07-28 Common Stock (10328) Direct
2023-11-13 Stock Option (Right to Buy) $17.47 D 6410 Disposed 2027-06-15 Common Stock (6410) Direct
2023-11-13 Stock Option (Right to Buy) $12.75 D 10000 Disposed 2028-06-14 Common Stock (10000) Direct
2023-11-13 Stock Option (Right to Buy) $3 D 20000 Disposed 2030-06-18 Common Stock (20000) Direct
2023-11-13 Stock Option (Right to Buy) $4.01 D 40000 Disposed 2031-03-29 Common Stock (40000) Direct
2023-11-13 Stock Option (Right to Buy) $3.31 D 40000 Disposed 2032-01-02 Common Stock (40000) Direct
2023-11-13 Stock Option (Right to Buy) $1.13 D 87500 Disposed 2033-01-01 Common Stock (87500) Direct

Footnotes

F1: This option, which provided for vesting in thirty-six (36) substantially equal monthly installments over three years following the date of grant on July 29, 2016, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc.

F2: This option, which provided for vesting in full on June 14, 2018, was canceled in the Merger.

F3: This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger.

F4: This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger.

F5: This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger.

F6: This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger.

F7: This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $81,375, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger.